text:
The election was held on 21 August, 2010. It was the first election since 1993 at which neither leader had faced an election before. On 24 June the governing Australian Labor Party replaced its leader, Kevin Rudd, with Julia Gillard after poor polling and Rudd’s leadership style had alienated the Labor caucus. The Liberal/National coalition were now led by Tony Abbott, who had replaced Malcolm Turnbull in 2009 (Turnbull himself replaced Brendan Nelson in 2008).
prime minister, was run by ‘faceless men’ and incompetent, and did not deserve re-election. The Abbott campaign gave particular attention to rising levels of unauthorised migration, and pledged firmly to 'stop the boats'.
The election resulted in Australia’s first hung parliament at the federal level since 1943. The Coalition and Labor won 72 seats each, four short of the total required to form government. One independent MP and one MP from the National Party of Western Australia supported the Coalition, while three others and one Green MP supported Labor. Gillard was able to form a minority government.
Julia Eileen Gillard was born 29 September, 1961. She was the Prime Minister of Australia from 24 June, 2010 to 27 June 2013 when she was replaced as Leader of the Labor Party. Gillard represented the electorate of Lalor, Vic from 1998 to 2013.
Friends thank you very much and friends thank you to Bob Hawke—thank you for that generous introduction. And thank you Bob for proving to us that you can make big change with strong leadership and by striving for consensus. It’s a great lesson, thank you Bob Hawke. And can I acknowledge too Kevin Rudd who is with us today a man of great achievement. A man of great achievements—with great achievements to lie in the future for our nation, thank you Kevin. And friends can I also acknowledge former Prime Minister Gough Whitlam who cannot be with us today but of course who inspired us all. Can I also acknowledge former Prime Minister Paul Keating who also can’t be with us today but of course drove so many of the economic reforms that make us a great nation. Can I thank Treasurer Wayne Swan and Deputy Prime Minister a great Queenslander, a great friend, for his words of welcome. And can I thank Anna Bligh, party president and Premier of this state for her words of welcome as well. And can I acknowledge that we meet on traditional lands, we meet on the lands of indigenous Australians. I pay my respects to them, to their elders past and present, in a spirit of reconciliation.
Friends, today I want to speak to you from my heart, I want to speak to you about my values and my vision for this country. Friends, I have believed all of my life in the power of hard work, in the importance of work, in defining a life in the importance of work, in earning your keep, in making sure you do your best every day. All of my life I have believed in the transformative power of education. That every child should get a great education. All of my life I have believed that we should show simple courtesy and respect to each other by caring for each other in times of need and all of my life I have believed that we can move forward with confidence. That our best days lie in front of us not behind us.
These are the values that I have taken with me all of my life, these are the values that will guide me as Prime Minister. Of course I learnt these values in my family home, I learnt them from my parents John and Moira who join us today, thank you Mum and Dad.
When my parents migrated to this country they didn’t come asking for a free ride, they came seeking a fair go, and they found it. They found it and they worked hard for it, when we first came to this country times were tough and Dad had to knock on many doors to get a job, but he got that first job and then a better second job and then he took other jobs to work hard for our family. My mother always worked as well and because of their hard work my sister and I were able to have a future, but I ask myself what would have happened when Dad knocked on those doors if there were no jobs to be had.
What would life have been like if my father hadn’t found work when we came to this country, and if understanding that, understanding the devastation that can flow from the absence of work that guided us when the global financial crisis threatened this country, because we wouldn’t have been asking that question about one man. We would have been asking that question about hundreds of thousands of Australians who would have been thrown out of work. Many of them may never have worked again.
We know in past economic downturns that workers who lose their jobs are at risk of never working again. We know in past economic downturns that young people who come of age in the economic downturn may never get their foot on the first rung in the ladder of life. They never get a job. Never get an apprenticeship and show that disadvantage five, 10, 15 years later.
So when the global financial crisis threatened this country, we said we were for jobs and I’m proud of it. I’m proud we did that.
And Australians, I acknowledge not everything went according to plan but look what we achieved together. We emerged from this global economic crisis, the worst global economic shock since the Great Depression. We emerged from it stronger than any other major economy in the world. We emerged from it with low unemployment. We emerged from it with inflation under control. We emerged from it with interest rates more than two percentage points less than when Mr Abbott and his friends left office.
Let’s have a look at the track record of creating jobs. In this country since 2007 we have created more than half a million jobs. In other advanced economies they have lost 16 million jobs –- 16 million working people who are now struggling to find a future for themselves and their families.
What does this mean? Well it means we’ve got a great opportunity for the future. It’s an opportunity we created together. An opportunity that government working with small business, working with families, working with unions, working with employers created for the future. We emerged from this downturn stronger than the rest of the world. That’s a fantastic opportunity but to seize that opportunity we’ve got to have careful management. We’ve got to have proper plans for the future and I have them.
And as Bob has rightly said, what do we hear from the other side of politics? We don’t hear about this great opportunity. We don’t hear about how we can build for the future as we emerge from these troubled economic times. No, all we hear from Mr Abbott is to be afraid, to be afraid as he goes around talking about debt, as he tries to sell you his slogans. But of course what Mr Abbott doesn’t tell you is he doesn’t tell you the simple facts. The simple facts that the global financial crisis caused debt and deficit for economies around the world and when we look at other major advanced economies, they have a debt, on average, 15 times greater than ours.
He doesn’t tell you that when you look at the debt of this nation, it’s the equivalent of someone who earns $100,000 a year having a $6,000 loan. That’s where our nation is positioned.
Now let me say this: I want to repay that debt. I definitely want to see this nation repay that debt, and that’s why I’ll bring the Budget to surplus in 2013 and it’s why each and every day of this campaign, every time I have announced that we would spend on a new priority, we have also announced we would make the matching savings because I will not delay bringing the Budget to surplus by one hour, by one day. The Budget is coming back to surplus in 2013.
And for all of Mr Abbott’s fear campaign, of course it’s Mr Abbott who’s splashing money around during the election. On average he’s spent a billion dollars a day, each and every day of this election campaign.
A billion dollars and he’s refused to put those policies and plans in for proper costing. He says, oh that doesn’t matter. A billion dollars a day and he’s refusing to come and see me in an economic debate. The real risk for debt and deficit, the real risk for debt and deficit in this campaign is Mr Abbott. Mr Abbott and his expenditure that will eat into our Budget surplus. Mr Abbott is the risk to our Budget surplus and to the future of the government’s balance sheet. Mr Abbott is the one that is causing debt and deficit in this campaign. That’s his track record.
And friends on the basis of what we have achieved together - the jobs, the strength of our economy –- I do want to build for the future. And in order to build for the future, you need to have a comprehensive plan for jobs. Now I’ve been talking about jobs all of this election campaign because I believe in work. I believe in people having the benefits and dignity of work. I’ve believed that all of my life. I believed it when we faced the global financial crisis in 2008. I believe it now and I believe it for the future.
Mr Abbott’s track record was to not support jobs when the global financial crisis threatened. To risk seeing hundreds of thousands of Australians out of work and he is seeking your trust today even though he has no plan for jobs.
Well my plan for jobs is that we will invest in the skills that our people will need to compete in the future. We will invest in the infrastructure of the future including the National Broadband Network and we will cut taxes for all businesses in this country. That’s good for business and it’s good for jobs, and what I say to people across Australia, is I want each of us to prosper. I want all of us to prosper –- and running an economy that offers the benefit of work is the secret to both. Each of us prospering and all of us prospering.
I am deeply, deeply troubled that in a nation like this one, we have too many children who are growing up in families where no-one works. The statistics are truly troubling. There are 246,000 families in this country, children growing up in those families and no-one has worked there for more than a year. There are 128,000 families, children growing up in them where no-one has worked in those families for more than three years and what the statistics tell us is if a child grows up in a family where no-one works, then they are likely to be unemployed themselves. They will be robbed of the prospects of a future, robbed of the benefits and simple dignity of work, robbed of the economic opportunities and personal choices that it brings.
Well friends, this isn’t good enough, and with my plan for jobs I want to extend the benefits of our prosperity to those families and to those children. That’s why during this campaign I’ve announced that we will ask the unemployed to step up again, to make sure that they are meeting their obligations to be looking for work.
I’ve said we would assist people to relocate to those parts of the country that can offer them the benefit of work. I want to put a priority on making sure that we do not see children inherit joblessness from their parents.
The prosperity of each of us, the prosperity of all of us –- it’s about a strong economy and it’s about having jobs. A job is essential for a family’s future. A strong economy is essential for a nation’s future. I will build that strong economy, investing in skills, investing in infrastructure, focusing on jobs, and families within the nation will be able to build their future with the benefits of work.
And when people have the benefits of work, I want them to have decent conditions. It is remarkable to me that Mr Abbott in this election campaign is trying to deny his words from the past. As recently as May this year, he was lauding WorkChoices in the Parliament, in the most important speech in the Opposition Leader can give: the Budget Reply speech. Telling us about the benefits of WorkChoices, telling us about his plans to re-introduce individual contracts, to take away unfair dismissal rights. These are the things that Mr Abbott has believed in all of his life. Well I’m proud we brought this nation through the global financial crisis. We created jobs. We created decent jobs because they stand on the shoulders of our Fair Work laws. Friends there should be no going back to Mr Abbott’s WorkChoices.
Friends, all of my life I have believed in the importance of work but I’ve also believed that education transforms lives. It transformed mine. I’m joined today by nephew Tom and by my niece Jenna. My nephew Tom has just finished his trade apprenticeship. Congratulations to Tom. My niece Jenna has her PhD in biotechnology. As my father is heard to say, in our family she’s the smart one, not me.
My niece, my nephew have those skills, they have those qualifications because they got a great education in a family home that valued education, that asked them to strive and do their best. But friends, the truth is that as we look around this great country there are too many children, too many children who don’t get the benefit of that great education, too many children who get left behind. It’s not good enough and it doesn’t have to be like this. I believe we can build a nation where every child from every family no matter where they are born in this country, no matter the circumstances of their birth, that every child in this country can get a great education and the opportunity to have their life transformed by it. We can achieve this, we can build this together and we should.
And friends, we can build this together on the foundation stones of the reforms we have already put in place. MySchool so we know what is happening in every school. No more hiding of under-achievement –- shining a light on it. Also, no more hiding excellence. We should understand which schools in this country are transforming the lives of the children within them. We should study those schools. We should share what they know with schools right around the nation.
We, of course are delivering a national curriculum and investments in better quality teaching. Mr Abbott wants to sweep these things away. But friends to guarantee every child in every family in every school a great education, we need to do more. We need to keep investing in trades education, to give kids opportunities to get into the trades. That’s why I am determined to keep building Trades Training Centres so that every secondary school student in this country has the opportunity to learn trades skills to participate in our National Trade Cadetship program to get the real skills that they will need for life and work, the real skills to get an apprenticeship, to set themselves up for the rest of their lives and if re-elected we will do that. We will build those Trades Training Centres, we will deliver that National Cadetship Program and it will transform lives.
And if we’re re-elected we will go further. We will reward the best teachers because they do the hardest work of all. We will reward the schools that are improving the most so that they can benefit from having achieved for the children in their classrooms. We will of course create a prestige qualification – the Australian baccalaureate – so students in our country can get a qualification that can hold its own on the world stage while studying our curriculum, studying about this country, studying about Australia. We will continue to deliver computers into school. We will empower school principals to take their schools on a journey of change, a journey of improvement, a journey to make sure that every child in every school gets a great education. And friends, we won’t rest until we have achieved that right around the country for every child in this country.
Mr Abbott of course says that it’s alright to take away the things that we want to provide to children in schools, to take the computers out of their hands, to shut down the Trades Training Centres. He wants to deny 1.2 million children the benefits of a trades education. He wants to take away the money we want to invest in better teaching, the money that today is enabling the best teachers to be paid more, to go to the classrooms that need them the most, and change kids’ lives. He wants to take that money away. He wants to end our program Teach for Australia, which brings into teaching the highest performing graduates. And of course, under Mr Abbott, you wouldn’t see Teach Next, the program we have designed to bring high achieving mid-career professionals into teaching so that they too can transform children’s lives. Well, I do not believe that’s good enough to let Australian children down. We’ve started the journey for the Education Revolution. We need to complete that journey for every child, in every school.
And friends, I understand for Australians right around this nation it can be tough, it can be tough getting up every morning and going to work, setting the alarm clock early, getting the kids out to school, making sure that the cost of living, the bills all add up at the end of the week. People are obviously facing cost of living pressures. And of course, we want to help Australians with those cost of living pressures. So what I say to Australians is we want to help them in a way that ensures that families have the benefits of work and that kids are in school. That’s why we have chosen to assist families with cost of living pressures by providing tax cuts. We want to make sure through our tax cuts which have been provided three years in a row, that families get to keep more of what they earn. We want to make sure through our education tax rebate and by its extension to school uniforms that we are helping families with the cost of getting kids to school.
We want to make sure that we’re helping families with the cost of child care centres, the very centres in which early learning will happen because of our new pre-school program. We want to be a partner in those costs and that’s why we’ve increased the child care tax rebate to 50 per cent. And if re- elected as Prime Minister, I want to do more. I understand that teenage children don’t cost less than younger children. In fact, everything I’ve ever heard suggests they cost a lot more. But our family benefits system at the moment is modelled on the assumption that kids are quite likely to leave school at 16 and go into the workforce. It is an assumption from an earlier age. We want teenagers in school. We want them learning the skills they will need for life and work, and that’s why, if re-elected, I will increase the family benefit for teenagers by more than $4,000. A help for parents with the costs of raising teenagers, but it will be tied to kids staying in school, in education and training, getting the skills they need. We want them in school today so that they are in a job tomorrow. That is vital for our nation’s future and for theirs.
Friends, our future should be about shared prosperity. It should be about work. It should be about skills. It should be about what’s happening in schools today. But it should also be our way of showing to each other care and concern. And there’s never a more important moment to show care and concern for each other than when someone faces an illness. Friends, we are the party of Medicare and I’m proud to say that in front of Bob Hawke today. We brought Medicare to this country. It’s stood the test of time and it has served us well.
But the reality is, when we came into office we inherited the legacy of Mr Abbott’s cuts. Mr Abbott’s billion dollars ripped out of public hospitals, which meant they were feeling stress and strain. Not enough doctors, not enough nurses, overcrowded emergency departments, people on waiting lists for elective surgery. We inherited Mr Abbott’s cuts, not enough trained GPs. It takes a long time to make a General Practitioner and if you’re asking yourself the question, why can’t I get a doctor’s appointment today, look to Mr Abbott’s cuts because they’re the reason why. We haven’t been training enough General Practitioners and it shows.
That’s why we will continue to invest in and reform health. We will train 1,300 new GPs to overcome the legacy of Mr Abbott’s cuts. We will train 3,000 more new nurses. We will train the health professionals we need for the future. We have increased the amount of money invested in health by 50 per cent and now we will reform for the future. More local control, more of a local say for doctors, nurses and the local community. The Federal Government stepping up to what it should do: taking the dominant share of funding for our health system. Making sure that we’re reducing waiting times in emergency departments from eight hours to four hours. Making sure that we are getting elective surgery performed on time in 95 per cent of cases. These are profound health reforms that we want to deliver for the future. Australians need them. They need them now. And we need them to have a health care system that can meet our needs as we age, as there are more older Australians seeking care in five, 10, 15 years time.
But friends, today I want to go further. I want to build on those health reforms as we move to a new future. Friends, we’ve had a lot of discussion in this campaign about the National Broadband Network. A lot of discussion about the power of this new technology. Now of course, Mr Abbott thinks it’s about sending an email, you might want to download a movie, but in any event he’s not going to build it. We understand that this technology is about transforming our economy so we’ve got a fair share of the jobs of the future. Our classrooms, so it doesn’t matter whether you’re sitting in a classroom in Brisbane or in Alice Springs, or in Perth, you can open the door to the world and see it in your classroom.
We also understand that this technology is about transforming how we deliver health care. Friends, it is disturbing to me, it’s unacceptable to me, it’s offensive to me, that if you live in rural and regional Australia you are up to three times more likely to die within five years if you are diagnosed with cancer than other Australians. Literally, your chance at life is less. And that is because it is harder for people in regional and rural Australia to get access to the services, to the health care professionals they need. Well I want to transform that. I want to transform it soon, and I want to transform it for the future, relying on the National Broadband Network. So today I announce that from the first of July next year, for Australians who live in rural and regional areas, and outer suburban communities where specialists are short, we will have a Medicare rebate which enables them to Medicare rebate their consultation using the internet now, and broadband tomorrow. So they can see the health practitioner they need from the offices of their local General Practitioner rather than moving town, moving city, moving state, which is what has to happen now.
Friends I ask you to imagine the power of this. Imagine having had an operation, you needed to go to a different place. Perhaps it was quite far from your home. You were distant from family and friends. You have had the operation and now you’re well enough to return back home. But of course operations require follow-up, they require monitoring and care. At the moment, to get that monitoring and care each and every time, you have to journey far from your home. And when we say far from our homes, of course that’s true in rural and regional Australia, but it is also true for people on the outskirts of our major metropolitan cities. It can be a long way in from the edge of town if you’re feeling sick, and you’ve just had an operation. Under this scheme you will be able to go to your local General Practitioner and consult face to face, through the power of the internet, and then evermore quickly through the national broadband, with your specialist, without having to go far from where you live, from the care and concern of your family and friends.
And we will build on that so from the 1st July 2012, we will be offering new benefits to all Australians. In this campaign, you’ve heard me talk about the GP After-hours Helpline. It’s the one that Mr Abbott wants to take away. It’s the helpline that you’ll be able to ring if something happens in the middle of the night. To speak to a nurse, to get access to a General Practitioner, to get access to the health advice you need. Well today friends, I announce that we will be using the power of new technology. So instead of just being on the phone, you can be on broadband. Instead of a voice at the other end of the line, there will be a person in your lounge room, and you will be able to talk to them about that health emergency. At night, from your own home.
I ask you once again to imagine the power of this, in the middle of the night: a child with a rash, in the middle of the night a child with a swelling – you don’t quite know, is it not very much? Is it something really serious? Well imagine, in your own home, being able to show the child with the rash, the child with the swelling, being able to get assistance and help through the power of broadband, through the power of the internet.
Being able to get some guidance in that moment when you’re truly anxious, truly anxious and don’t know what to do next. About whether this is something benign and just staying at home with mum and dad and loving care is all that is required. Whether you need to see a doctor the next day in your own community or whether it’s something really serious and you should be thinking about calling an ambulance or driving to the emergency department of your local hospital.
Imagine being able to do that. Not by talking over the phone, desperately trying to describe what you see and anxious you’ve got the description wrong, but by being able to show a healthcare professional what it is you’re worried about and getting the advice you need. This is the future of healthcare, and for our GP After-Hours Line, it starts on the 1st of July 2012.
And of course, this can’t happen, it can’t happen if we don’t have the broadband. It can’t happen if we don’t have the GP After-Hours Helpline. It can’t happen if Mr Abbott is elected as Prime Minister because he is going to stop both. Stop the national broadband, stop our GP After-Hours Helpline. Once again, Australian families deserve better than that. They should be having access to the health care of the future and if re-elected Prime Minister I will provide it.
Friends, all of my life I’ve believed in work, I’ve believed in the power of education, I’ve believed that we show decency and respect by turning to each other with care and concern. But I’ve also believed in something else. I’ve believed in something else, and that is that we should not be afraid of the future. The best days of this country are in front of us, not behind us. I am an optimist. I am so hopeful about this country’s future. We’ve emerged from a profound crisis strong and now we can build together. But during this election campaign as I’ve talked about my economic plan, my plan for jobs, my plan to get unemployed families working, as I’ve talked about my plan for education, as I’ve talked about delivering health reform, lifting cost of living pressures on Australians, as I’ve talked about the things we’ve done as a Government including the achievement of providing to our pensioners an historic increase now and providing increased superannuation for the future of all Australians, as I’ve talked about those things Mr Abbott has gone around with his slogans. That’s all he’s talked about.
And let’s look at Mr Abbott’s slogans. He says he wants to end debt but he’s the risk to the surplus –- a billion dollars a day, no proper costings. He says he wants to end waste but isn’t the greatest waste the waste of the skills and capacities, the livelihoods, the hope, the prospects of improvement of Australians. We invested in those skills and capacities. We invested in their prospects and hope when we faced the global financial crisis, and we will continue to invest in them for the future.
And then Mr Abbott says no new taxes but his whole campaign is founded on a new tax. His Budget numbers don’t add up now but they’d look even worse if he wasn’t going to put a tax on groceries. A tax on everything you buy, every time you go to the shops. He wants to put company tax up. I want to put it down. He wants to increase cost of living pressures on working Australians and their families. I want to assist with those cost of living pressures. He stands for more tax in this campaign. I stand for tax cuts, tax benefits, tax relief for every Australian business.
And Mr Abbott says to you he wants to stop the boats but today we’ve actually found out what this plan means. Just imagine it –- a Commander of one of our patrol boats out on the high seas. What Mr Abbott wants that Commander to do is to take their eyes off the safety of their crew, take their eyes off the ocean, take their eyes off people smugglers, go inside the cabin and give him a call. That’s Mr Abbott’s plan to stop the boats. And then presumably, from the safety of Kirribilli as he watches luxury yachts go by, Mr Abbott is going to provide some advice to that Commander about how to stop the boats. Friends, this is a nonsense. This is a nonsense and every Australian will see through it I’m sure. I trust the skills, capacities, energy, decency and dedication of our hard-working Defence personnel. We put the nation’s safety in their hands. We do it for a reason and my trust is with them and for them. That’s what I believe in.
Friends, the election day will fast be upon us and Australians, as we move towards that election day, are going to be making a choice. I do not believe the nation should choose Mr Abbott’s negativity. We’re better than that. We are so much better than that. Friends, with you here in this building, with Labor legends in this room, what I want to say to you is we know the Labor movement, the Labor Party, this nation, is so much better than that. We are a confident, optimistic people. There is no challenge too great, that we can’t tackle it, if we do it together.
Ben Chifley spoke to us about that light on the hill in a different age, in a different nation, in a different time. President Barack Obama inspired a nation by saying ‘yes we can’. Well friends, I’m too humble to compare myself to either Ben Chifley or Barack Obama, but I am asking you, I am asking you when you vote on Saturday, to say, as you cast that vote: yes we will. Yes we will move forward with confidence and optimism. Yes we will keep our economy growing stronger day by day. Yes we will offer people the benefits and dignity of work. Yes we will transform our education system so every child, every child gets the benefit of a great education. Yes we will show care and concern for each other through a decent health care system. Yes we will work together and tackle the challenge of climate change. Yes we will embrace the technology of the future by embracing the National Broadband Network. Yes we will close the gaps between indigenous and non-indigenous Australians and we will recognise the first Australians in our Constitution. Yes we will move forward together.
Friends, that’s what next Saturday is all about. Thank you very much for listening to me today and I ask you to say that we will move forward together.

industry_corpus2: Health & Medicine


text:
A final companion to books from the Simpsons - do you read me?!
Whether it is a representation of a Homeric moment, a snapshot of the hellish ten-year-old troublemaker Bart or a solemn intellectual disposition featuring Lisa, “A Final Companion To Books From The Simpsons” is a new volume about the books which appeared in The Simpsons. Assembled by French graphic designer Olivier Lebrun and published by Yellow Press, this final collection is displayed in faint yellow and shades of grey screenshot photos of book references that exist within the Simpsons universe, whether taken from real life or invented to suit the plot of the episode. From ‘Flander’s Bible” and “Fear of Flying”, to “Crazy Things Old Ladies Say” and “The Big Book of British Smiles”, to “Ein + 1 = 0”, “From Loser to User” to “Things Fall Apart” an anthology of 339 titles which appeared throughout the years in the legendary tv series.

industry_corpus2: Literature & Emotions


text:
Can you make the subscription titles from the e-mails that Tableau sends out dynamic?
I was looking to add the date the e-mail is sent to the title of the Tableau e-mail.
The simple answer is you cannot add any dynamic value to the Subject of a subscription.
As you see the Subject can only accept text input which is then passed on to the text input of the subject line of your mail client.
What you can do instead is create a top section of the dashboard which looks like a header where you can create calculation for today's date. So whenever the subscription mail is sent the image that is shown in the body will have the date and any other important info displayed on the top.
Ok, thank you for your response!

industry_corpus2: Computing & Telecommunications


text:
Days 26 & 27 – Two zeros in L.A.
On the trail we crafted a list of all the things we wanted to do when in L.A. This included things like airing out our wet tent, condensing our first aid kits, taking out qtips and colloidal silver from every resupply box since we aren’t using them as quickly as we had anticipated, and other odds and ends.
Even though we had 2.5 days to do all that we wanted, there wasn’t enough time. Our list didn’t include meals with family and visiting with friends- the things that became more important once we were settled.
The last 2 days were nice but felt like a whirlwind. We both look forward to returning to our simple life on the Pacific Crest Trail.
On the trail there is a limited amount of food choice and as we get closer to our resupply point the options become even more sparse. We did a great job of creating variety in our bars and dinners but there is only so much backpacking appropriate food one can eat. There is something refreshing about that simple way of eating.
In towns and even more so now in L.A., Laurie found herself getting overwhelmed with options. Everything sounded good and knowing that we may not have it for the next 5 months made it feel even more urgent to eat everything in sight.
Needless to say, we both over ate. It is so hard when there is an endless supply of tasty food! We haven’t encountered “hiker hunger” yet but can sense it is coming. At least for the first few days of this next section we will be well prepared with full stomachs and tasty leftovers!
Sunday morning we head back to Wrightwood and back to the PCT. Our friends Josie and Matt will be joining us for a day hike and we look forward to sharing the day with them.
Laurie spent Saturday visiting her mom in Oakland, CA while Andy continued running errands and checking things off the list.
He also made time to nap, a rare treat for us on zero days thus far.
Our packs are packed, leftovers are in ziplocks, and our clothes are clean. We still stink, but at least we’re not dirty. No matter how many times we shower, our arm pits still stink. Oh well. We just have to embrace our new smell.
Tonight we are grateful for airplanes which allow for quick visits with family and readily accessible power outlets.

industry_corpus2: Travel & Geography


text:
CONSTRUCT offers websites that all are built on the world class platform of WordPress.
WordPress designers have gone to great lengths to create designs and backend coding to make it simple to get your website up quickly and at substantial savings.
This allows us to spend the important part of site construction working on content and building a great web presence.
E-mail accounts, Google analytics, Contact forms, Newsletter sign up form.
There is no one way to build a site and variables are a constant. Use these prices as a basis of what you will receive. The prices shown are subject to change.


text:
A backsplash is an opportunity to get creative in your kitchen. While you could use ceramic, granite or glass tiles, you can also choose an unconventional tile such as plastic ceiling tiles. These tiles are affordable and easy to install. Many are designed to look like traditional tin ceiling and come in a wide variety of solid colors and metal finishes. You can easily create a backsplash from plastic ceiling tiles to complement any decor style, from country to modern.
Measure the length of the wall where you intend to install the backsplash, using a tape measure. Mark the center of the wall at the top and bottom edges.
Cut off the tip of the tube of all-purpose adhesive caulk at a 45-degree angle at the 1/4-inch mark, using a utility knife. Puncture the seal inside the tip of the tube with the caulk gun's built-in puncture tool. Insert the tube, tip first, into the caulk gun.
Place the plastic ceiling tiles on a work surface with the front side facing downward. Apply a 1/4-inch bead of adhesive around the perimeter of the back side of the tile, 1/2 inch in from the edges. Wet your finger and flatten the bead.
Apply a 1/4-inch bead of adhesive to the center of the back side of the tile. Flatten the bead of adhesive with your finger.
Cut four, 1-inch by 1-inch strips of double-sided mounting tape with scissors. Place them 3 to 6 inches inside the corners of the back of the tile.
Position the tile on one side of the center mark on the wall. Ensure that the bottom edge is flush against the joint between the wall and the counter. Press the tile into place. Position the second tile against the wall on the opposite side of the center mark so that it butts up against the first tile.
Complete the first row, placing the tiles end-to-end vertically. Work your way up the wall in rows until you complete the backsplash.
Lay the edge trim on a work surface with the front side facing downward. Dry-fit the edge trim strips over each joint between tiles and cut them to size, using scissors.
Apply a bead of adhesive to the back of each piece of edge trim. Press the trim firmly into place to cover the joints between tiles.
Select plastic ceiling tiles that will complement or accent your existing walls, counters, floors and cabinetry.
Follow safety precautions on the adhesive caulk tube.
Morrissey, Jonah. "How to Install a Backsplash Using Plastic Ceiling Tiles." Home Guides | SF Gate, http://homeguides.sfgate.com/install-backsplash-using-plastic-ceiling-tiles-34764.html. Accessed 24 April 2019.

industry_corpus2: Real Estate & Construction


text:
For this post, I’ve gone into my archives and updated one of my earliest articles.
Here’s a photo of me on the coast of Maine with a treasure I found washed up on shore.
Seeing the not quite picked-clean bones of this huge fish reminds me of similar encounters at a time when I was young and innocent, playing in the sand with my silver spoons and plastic bucket, trying to dig to China. I remember how sand crabs skittered about while I dug deep holes that filled with ocean water seeping in under the beach. I remember finding the shield-like remains of a spiny horseshoe crab with its stiff dagger tail. And one peaceful afternoon, two men dragged a large thing through the surf and onto the sand nearby. A sleek, grey, smooth-skinned body with a long tail, and side and dorsal fins. I was little and the thing was huge, and it was a shark.
That creature laying on the sand made me wonder what else swam out there in the deep, among the rushing waves just beyond the shore. What else was out there that I couldn’t see? Close enough for swimmers to capture, close enough to swim among the swimmers.
I decided I didn’t want to be one of those deep-water-swimming-with-creatures kinds of people. I’m perfectly happy to watch the waves for hours, feel my toes leave impressions in the warm sand, smell the salt in the air, hear the gulls cry. At peace with the forever cycle of sea meeting land in a rush and swell, a falling back, and a reaching out once more.
The sea and me, we have an understanding: if I don’t go in too deep, it won’t eat me alive. It’s not the fear of drowning that keeps me rooted in ankle-deep surf. I can swim just fine. No, it’s the things in the water I can do without. And I’ve always been okay with this perfectly logical fear I have.
Then I took my oldest daughter on a Caribbean cruise for her 21st birthday. We explored Mayan ruins in Cancun, hiked through a waterfall in Jamaica, visited a place called Hell. It was all wonderfully normal, until she wanted to swim with stingrays. AND she wanted me to join her. How sweet of her to think of me. The water would be warm and clear, she said. Clear enough to see all those creatures living in the ocean.
At the time of the cruise, I hadn’t been introduced to AJ Jackson (of This New Mountain) and her head-on approach to dealing with fear, but I knew deep down if I let go of this chance to share something remarkable with my daughter, I would always regret it. And a part of me actually did want to [shudder] swim with stingrays.
I talked myself into it and out of it dozens of times. I was still talking to myself as I followed my daughter down the ladder on the side of the sightseeing boat. I changed my mind again, but I couldn’t climb back up, someone was already clanging down the ladder above me. My heart pounded. I tried not to look at the water below as I stepped onto the bottom rung. To keep from hyperventilating, I had channeled deep Kung-Fu-Lamaze breathing for a good fifteen minutes up to this point. No other options presented themselves besides shoving the person above me off the ladder. I took a few more slow, even breaths, told myself to just do it, and dropped into the warm ocean.
I expected to have to push off the bottom and swim to the surface, instead I touched solid “ground” after a few feet. The water resting over this pristine reef was only armpit deep. The sand spread out at my feet soft and white and unmarred as far as I could see. No shells, no seaweed, no creatures, nothing but sand. It was as if someone had swept it clean just for me. This wasn’t so bad. I could do this.
Soon a murmur started from a group of people bobbing in the calm farther away from the boat and me, and closer to the open sea. Shadows slid through the water, dark cloaks winging toward us. I screamed along with everyone else – tenor and soprano voices mixed together, men and women alike.
But these stingrays were not there to hurt us. They were more like dogs racing in for the treats the tourist boat always brought along to bring them close. The rays hugged our legs and spun around us. My daughter, the adventurous child, hugged one back. I stood as still as possible and took photos of rippling cloaks and tiger-eyes unblinking. Soon the creatures turned and swept back the way they came.
I still don’t like deep water, won’t go in it, preferring slow walks along the edge of my mind and the surf. I’m comfortable with this fear, its limitations and its limits. I suppose I’ve always known that some things are more important than fear, I just don’t like to have to practice that particular piece of wisdom. But now I can say I swam with stingrays – and I never have to do it again.
Is there a fear that keeps you from doing something you’ve always wanted to do? Is it time to take a few deep breaths, pull yourself up by your bootstraps and jump in?
This entry was posted in Fear Less Fridays and tagged Ambrose Redmoon, courage, facing your fears, fear less, lessons from life, living life to the fullest, swimming with stingrays by Cate Macabe. Bookmark the permalink.


text: Today’s special freebie is a notepad mockup PSD scene containing paper notepad, drawing pen and coffee cup. Use the PSD file to mockup your own hand-drawn illustrations, sketches or designs using the smart-object layer. You can easily change the color of the scene background. Happy download!


text:
Visitors to Ningaloo Marine Park can swim with majestic humpback whales for a third year running, with the new trial season commencing off the Coral Coast.
The Minister for Environment has also approved the continuation of the in-water interaction trials for the 2019 and 2020 seasons.
The move will attract thousands of tourists to visit the World Heritage-listed Ningaloo Coast to interact with the massive marine mammals as they make their way north to their Kimberley calving grounds.
The Coral Coast is the only location in Australia where visitors can swim with migrating humpback whales.
With the trial re-commencing in Coral Bay last month and in Exmouth this month, visitors can also experience whale sharks, manta rays and turtles, which are usually present while humpback whales are migrating through the area.
The in-water interactions with humpback whales trial is managed by the Department of Biodiversity, Conservation and Attractions under strict licence conditions, supported by a research and monitoring program.
During the 2017 trial, more than 200 in-water interaction tours with humpback whales were conducted with about 1,700 in-water participants.
The McGowan Government is working with tour operators and key stakeholders with a view to transitioning the trial to a licensed industry over the next two years, which aims to create jobs and boost the local economy.
"It's unique experiences like these that set Western Australia apart from other tourist destinations. Our amazing coastline means people who come visit Australia to simply whale watch can now take it up a notch and swim with the humpback whales - thanks to the continuation of this trial.
"My Government's priority is to diversify the economy and create jobs for Western Australians. Trialling experiences like these is another way we can attract more visitors to our State and bring about a boost to our local communities that host these exceptional experiences."
"We are continuing to assess and develop this new and innovative tourism experience, but visitor research from the first two years of the trial indicates that visitor satisfaction is very high and there are no indications of negative impacts on the whales.
"For this reason we are continuing the trial for a third year, and are working with operators towards establishing in-water humpback whale interactions as a long-term industry that ensures the whales are protected and appreciated in a sustainable way.
"The abundance and diversity of marine megafauna is one of the reasons the Ningaloo Coast was inscribed on the World Heritage List in 2011, and the area continues to provide outstanding nature-based tourism through its whale shark and humpback whale interactions."
"The McGowan Government is committed to sustainable tourism that provides benefits to regional economies, and the extraordinary opportunity to swim with these ocean giants is a big drawcard for visitors to Australia's Coral Coast.
"Facilitating humpback whale experiences has been an exciting development that is gaining interest from around the world, and I am looking forward to seeing the industry mature and become one of Western Australia's most significant attractions."


text:
LOTS of superhawk parts, forks, complete plastic etc.
FS: 1998 Superhawk w/ Numerous Upgrades - Great Shape!
Anyone have a Stator laying around?
Right Hand (Black) clip-on Handlebar wanted.
WTB: Anyone has an extra stock air filter?
Rear Brake Lever (New In Package)!
right case cover wanted....dont care about the condition..
Still need a Right Fork, bros.
Looking for right side mirror!
Rear Brake Lever (NIB) and other misc.
1998 Superhawk VTR1000F FOR SALE...MINT!!
Cheap low mile 99 for sale in FLA.
WTB: Left front brake rotor.
lockhart phillips aftermarket lower for sale!!

industry_corpus2: Automobiles


text:
You must buy a minimum of 5 due to manufacturer packaging.
Both ornate and absolutely eye-catching, the Marquis collection boasts a formal pattern that is excellent for anyone looking to create a refined, yet hospitable setting. With this flatware, a sophisticated touch to your table is within reach. This European size dinner fork is constructed of extra heavy-weight 18/8 stainless steel with a mirror polish finish. It measures 8 1/2" in length and includes four tines.
Larger than more traditional forks, this European-sized style offers more at the table.
Great Dinner fork to have with the rest of the set. Came to me in great time an had no issues when i got them. Like the great look they have an will be ordering more soon.
I will not and do not own " Holiday Silver", this is my alternative, to the expensive, overrated flatware. This is perfect for finer dining, or to use at home for special occasion place setting. 2 packs should last basically forever. They are very heavy and well made. and larger than a standard dinner fork, for a formal presentation.
Great silverware. Very good quality, sturdy, heavy, and well done. No sharp edges, no burrs, and it feels good in the hand and mouth. The Marquis pattern is stylish and understated. Very pretty, without being gaudy. I'd give it 5 stars for quality, but this is the "European" size, which I didn't know meant Jumbo. I like long handled silverware, so the length is fine, but the part you put in your mouth is pretty big on this size. (My husband made me go back and buy the regular size, as well.) The set of 12 is perfect for me, as I never run out anymore. These run through the dishwasher beautifully, No rust spots, no water spots, and no scratches. I've had them long enough to see wear, and I don't see any issues. It's great silverware. Don't hesitate.
This is a great line of flatware by Marquis! These dinner knives are smaller in size and great for salad courses!! Great material will withstand a lot of use! Beautiful!!
Save Up To $1.45 with our Recommended Product!
Consider this Acopa 18/8 extra heavy weight stainless steel european table fork! This polished fork will contribute to your simple yet elegant tabletop display. Acopa flatware is designed to stand up under the rigor of daily use, making it perfect for your restaurant or bar! This is a great quality fork at a much lower price!

industry_corpus2: Others


text:
Graduate students may opt to pursue their studies in either Animal Welfare or Human-Animal Interaction within the Department of Comparative Pathobiology. The objective of the training program is to prepare students for careers in research, teaching, extension/engagement and service related to the sciences of Animal Welfare and/or Human-Animal Interaction. The core aim of the Animal Welfare program is to facilitate the well-being of animals through understanding and applying concepts pertaining to animal ethology, physiology, psychology, husbandry and management, ethics and economics. The core aim of the Human-Animal Interaction program is to evaluate both the beneficial and adverse effects of interactions between humans and animals for both the human and animal counterparts. Related topics include: animal-assisted intervention, service animals, dog bite prevention, zoonotic diseases, and broken bonds between humans and animals. Employment following degrees in either or both areas may be in a variety of institutions, such as academia, industry, or private practice.
The training program is designed to attract students with diverse professional, cultural, and geographical backgrounds. We seek students with a range of expertise and interests, including animal behavior, ethics, biology, zoology, sociology, animal sciences, psychology, veterinary medicine, epidemiology, public health or other closely related fields. Applicants are required to have completed at least a BS or BA degree by the start of the position. All applicants should have a keen interest in strong research methodology and appropriate statistical analysis. Students must be willing to adapt to an interdisciplinary team approach involving animal- and/or human- focused researchers. Therefore, excellent interpersonal communication skills are essential.
Students are encouraged to tailor their individual programs with appropriate coursework to meet their needs and required credit hours as advised by their graduate committees. Coursework may be chosen from a variety of academic disciplines to provide understanding and competence in the primary area of research. At minimum, students are expected to complete a class in animal welfare and ethics. Each program of study will include coursework in the Department of Comparative Pathobiology as well as external Departments, such as Animal Sciences, Biology, Zoology, Philosophy, Psychological Science, Child Development and Family Studies, Educational Studies, Statistics, and others. The faculty in these departments may also serve on the students’ graduate advisory committees.
The following list provides a sample of appropriate courses for students seeking to focus their graduate programs in Animal Welfare and Human-Animal Interaction.
* CPB 61800/GRAD 61200 may be taken to satisfy the department’s ethics course requirement.
All students in the program will be affiliated with the Center for Animal Welfare Science (CAWS) and the Center for the Human-Animal Bond (CHAB). Each center hosts leading experts in the associated field of study. Association with the centers promotes interdisciplinary collaboration and world-class mentorship in topics related to Animal Welfare and Human-Animal Interaction. Students will be encouraged to participate in other CAWS, CHAB, and departmental activities including: participation in the collegiate animal welfare judging competition, assistance with teaching of undergraduate courses and outreach activities, development of additional research questions related to the main project and travel to present research findings. Professional development opportunities are also available.
For currently enrolled students, Purdue awards a number of Fellowship Incentive grants on a competitive basis (https://www.purdue.edu/gradschool/funding/) for students applying for extramural support from selected agencies or programs.
The American Psychological Foundation also offers a variety of awards and grants each year. The APA Science Council web page offers links to these opportunities and can be found at: http://www.apa.org/about/awards/index.aspx.
The College of Veterinary Medicine at Purdue University values, nurtures, and respects all members of its community and ensures an environment of inclusive excellence where all students, faculty, and staff are inspired and empowered to achieve their full potential. Purdue University is an EEO/AA employer fully committed to achieving a diverse workforce. All individuals, including minorities, women, individuals with disabilities, and protected veterans are encouraged to apply.

industry_corpus2: Subject Education


text:
INTERNATIONAL WORKSHOP ON Data Analytics for Dynamic Environments (DADE2015) (http://kat.ee.surrey.ac.uk/DADE2015/index.html) held in conjunction with the 2015 IEEE 81st Vehicular Technology Conference (VTC2015-spring) that will take place between 11 to 14 May 2015 at the University of Strathclyde, in Glasgow, Scotland.
This workshop will explore the data analytic solutions to extract actionable information from real time information in dynamic environments, such as vehicular networks and smart city environments.
The workshop aims to gather researchers, application developers, and industry to present and discuss data analytics and evaluations for real time and context aware applications.
Workshop papers will be published in IEEE Xplore together with the VTC 2015 Spring conference proceedings.
The workshop will take place one of the days of the VTC2015-spring Conference (11 to 14 May 2015).


text:
Joy Villa showed up to the 2019 Grammy Awards in what's sure to be one of the most controversial ― and most talked about ― red carpet looks of the night.
Singer Joy Villa, who attended the Grammys past year in a gown decorated with a fetus, dressed as President Donald Trump's wall to Sunday's 61st annual Grammy Awards.
"This is the wall", said Villa, holding a red "Make America Great Again" purse and pointing to her silver steel-colored dress.
Villa took to Instagram to share her motivation for the outfit.
Villa said she supports President Donald Trump's views on immigration, which she believes are often wrongly associated with racism and xenophobia. 'I am totally for President Trump, and it's only been one year.
Turning around she revealed Trump's "Build The Wall" slogan.
Gepostet von Entertainment Tonight am Sonntag, 10. Ricky Rebel strode the red carpet in a blue jacket emblazoned with the words "Keep America Great" and "Trump 2020" over a white blouse, pants, and high-heeled knee-high boots.
In 2016, the organising committee for the Tokyo 2020 Olympics outlined plans to make their medals from recycled gadgets . Next year's medals will be made in part from metal recycled from cellphones and small electronic devices.

industry_corpus2: Film & Entertainment


text:
This role is responsible for monitoring, reporting, analysing and projecting Honda’s performance, market trends and competitor activities, taking account of internal factors, market trend data and economic conditions.
The most important aspect of this role is the accurate and timely input of data into the COSMOS system. By doing so, the role contributes significantly to achieving sales forecast accuracy by optimising the mix in harmony with the budget plan and the market opportunity.
The role reports to the Business Planning Manager and will be responsible for supply availability, and the early identification and communication of supply risks and opportunities.
Analysis to provide market forecasts, economic outlook and social trends in particular to identify market opportunities and threats.
Input an agreed accurate sales forecast at MTOC level to Honda Motor Europe (HME).
Issue relevant reports related to HME-UK’s sales performance to key stakeholders on both a regular and ad-hoc basis.
Effectively communicate daily registration and market performance across the business enabling an “at a glance” evaluation of the current position.
Maintain a database of key information including, detailed market analysis, economic forecast and conditions, Honda sales performance, model launch and campaign results.
An analytical mind with the ability to translate the analysis into business proposal.
Significant experience in the automotive sector or in a ’third-party sales channel’ environment.


text:
Ruconest is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).
Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks.
Initiate treatment with Ruconest under the supervision of a qualified healthcare professional experienced in the treatment of HAE.
Appropriately trained patients may self-administer upon recognition of an HAE attack.
The recommended dose of Ruconest is 50 U per kg with a maximum of 4200 U to be administered as a slow intravenous injection over approximately 5 minutes.
If the attack symptoms persist, an additional (second) dose can be administered at the recommended dose level. Do not exceed 4200 U per dose. No more than two doses should be administered within a 24 hour period.
Store Ruconest in the original carton and protect from light prior to reconstitution.
Do not use after expiration date on the product vial label.
Water for Injection is not included in the Ruconest package.
Use aseptic technique to reconstitute, mix the solution, and to combine the reconstituted solution from more than one vial ( see Reconstitution [ 2.3] and Administration [ 2.4]).
Do not mix or administer Ruconest with other medicinal products or solutions.
Discard all partially used vials after treatment.
Sterile Water for Injection (diluent) - At least 14 mL per vial of Ruconest requiring reconstitution.
Commercially available vial adapter and syringe luer lock or large bore needle. If using a syringe with vial adapter, use a new vial adapter for each vial of Ruconest and diluent.
The procedures below are provided as general guidelines for the reconstitution and administration of Ruconest.
Ensure that the Ruconest vial and diluent vial are at room temperature.
Remove the flip caps from the Ruconest and diluent vials. Treat the vial stoppers with the antiseptic wipe and allow to dry.
Using the syringe/needle or syringe/vial adapter, withdraw 14 mL of sterile water for injection from the diluent vial.
Remove the syringe and transfer the diluent to the Ruconest vial. Add the diluent slowly to avoid forceful impact on the powder. Swirl the vial slowly to mix and avoid foaming.
Repeat this procedure using another 14 mL of diluent and a second vial of Ruconest.
If the same patient is to receive more than one vial, the contents of multiple vials may be pooled into a single administration device (i.e., syringe).
Inspect Ruconest visually for particulate matter and discoloration after reconstitution and prior to administration. The reconstituted solution should be colorless, clear, and free from visible particles. Do not use if the solution is cloudy, colored, or contains particulates.
Ruconest vial is for single-use only.
Use the reconstituted product immediately, or within 8 hours stored at 36ºF - 46ºF (2º - 8ºC). Discard partially used vials.
Do not mix Ruconest with other medicinal products. Administer Ruconest by a separate infusion line.
Use aseptic technique when administering Ruconest.
Follow recommended venipuncture guidelines for initiating intravenous therapy.
Administer Ruconest by slow intravenous injection over approximately 5 minutes.
For self-administration, provide the patient with instructions and training for intravenous injection outside of a clinic setting so patients may self-administer Ruconest upon recognition of symptoms of an HAE attack ( see Patient Counseling Information [ 17]).
After administration, immediately discard any unused product and all used disposable supplies in accordance with local requirements.
Ruconest is available as a lyophilized powder for reconstitution for injection in a single-use 25 mL glass vial. Each vial contains 2100 U of rhC1INH.
Ruconest is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products.
Ruconest is contraindicated in patients with a history of life-threatening immediate hypersensitivity reactions to C1 esterase inhibitor preparations, including anaphylaxis.
Severe hypersensitivity reactions may occur [see Patient Counseling Information (17)]. The signs and symptoms of hypersensitivity reactions may include hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis during or after injection of Ruconest. Should symptoms occur, discontinue Ruconest and institute appropriate treatment. Because hypersensitivity reactions may have symptoms similar to HAE attacks, treatment methods should be carefully considered.
The serious adverse reaction in clinical studies of Ruconest was anaphylaxis.
The most common adverse reactions (≥ 2%) reported in all clinical trials were headache, nausea, and diarrhea.
The Ruconest clinical development program evaluated a combined total of 940 administrations in 236 subjects (symptomatic and non-symptomatic). In clinical studies, a total of 205 symptomatic HAE patients received treatment with Ruconest for a combined total of 650 acute angioedema attacks. Among these HAE patients, 83 were treated for a single HAE attack and 122 were treated for multiple attacks.
Three randomized, placebo-controlled clinical trials (RCTs) were conducted in which 137 patients experiencing acute HAE attacks received Ruconest (either an initial 50 U/kg or 100 U/kg body weight dose) or placebo (saline solution).
Table 2 shows all adverse reactions (ARs) in the RCTs, compared with the placebo group.
MedDRA: Medical Dictionary for Regulatory Activities, version 15.0.
** Events only occurring in placebo patients are not listed.
In a total of seven RCT and OLE studies, 205 patients experiencing acute HAE attacks were treated with Ruconest for a total of 650 HAE attacks. Included in this population were 124 patients who were treated at the 50 U/kg dosage strength for one or more attacks.
Table 3 shows adverse reactions in ≥ 2% of patients in any Ruconest group for the integrated dataset combining all seven RCT and OLE studies in patients experiencing acute HAE attacks.
As with all therapeutic proteins, there is potential for immunogenicity. Pre- and post-exposure samples from 205 HAE patients treated for 650 acute attacks with Ruconest were tested for the antibodies against plasma-derived C1INH or rhC1INH and for antibodies against host-related impurities (HRI). Testing was performed prior to and after treatment of a first attack and subsequent repeated attacks at 7, 22 or 28, and 90 days after Ruconest treatment.
Prior to the first exposure to Ruconest, the frequency of anti-C1INH antibodies varied from 1.2% to 1.6% of samples. After the first exposure, the frequency of anti-C1INH antibodies varied from 0.6% to 1.0% of samples tested. After repeated exposures, the frequency of anti-C1INH antibodies varied from 0.5 to 2.2% of samples tested. The frequency of anti-HRI antibodies was 1.0% in pre-exposure samples, and after the first exposure varied from 3.5% to 4.6%. After repeated exposure, the frequency of anti-HRI antibodies varied from 5.7% to 17% of samples. At least 10% of subjects formed a specific antibody response to Ruconest after five treated HAE attacks. No anti-C1INH neutralizing antibodies were detected. Observed anti-C1INH and anti-HRI antibodies were not associated with adverse clinical findings.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Ruconest with the incidence of antibodies to other products may be misleading.
Pregnancy Category B. Studies performed in rats and rabbits at doses up to 12.5 times the human dose of 50 U/kg could not exclude an effect on embryofetal development. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Ruconest should only be used during pregnancy if clearly needed.
The safety and efficacy of Ruconest administration prior to or during labor and delivery have not been established. Use only if clearly needed.
It is not known if Ruconest is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ruconest is administered to a nursing woman.
The safety and efficacy of Ruconest were evaluated in 17 adolescent patients (13-17 years of age) treated for 52 HAE attacks. Eight out of 17 (47%) adolescent patients experienced adverse reactions. No serious adverse reactions were reported in these patients. The most common reactions (occurring in at least 2 patients) were: abdominal pain, headache, and oropharyngeal pain.
The clinical studies of Ruconest included seven patients older than 65 years. The clinical studies included an insufficient number of patients in this age group to determine if they respond differently from younger patients.
Ruconest is a recombinant analogue of human complement component 1 esterase inhibitor for intravenous injection. Ruconest is purified from the milk of transgenic rabbits, and supplied as a sterile, preservative-free, white/off-white lyophilized powder for reconstitution for injection. One U of rhC1INH activity is defined as the equivalent of C1 esterase inhibiting activity present in 1 mL of pooled normal plasma.
Ruconest is a soluble, single-chain glycoprotein containing 478 amino acids, with a molecular mass of 68 kDa, of which approximately 22% comprises oligosaccharide structures. The primary and secondary structures of the molecule and target protease selectivity are consistent with those of plasma-derived C1 esterase inhibitor.
Each vial of Ruconest contains 2100 U of rhC1INH, 937 mg of sucrose, 83.3 mg of sodium citrate dihydrate and 1.0 mg of citric acid monohydrate. After reconstitution with 14 mL of sterile Water for Injection, each vial of Ruconest contains 150 U of rhC1INH per 1 mL in a 20 mM sodium citrate buffer with a pH of 6.8. Ruconest does not contain preservatives and each vial is for single use only.
Ruconest is purified from the milk of transgenic rabbits. The rabbits are maintained in a closed colony that is controlled and routinely monitored for specific pathogens. The skimmed milk is screened for adventitious contaminants prior to further manufacture. The manufacturing process has been validated to demonstrate adequate capacity for removal and/or inactivation of viruses ( Table 4). Ruconest contains less than 0.002% of host-related impurities.
e Not tested because SD chemicals are present in the starting material.
C1 esterase inhibitor (C1INH) is a normal constituent of human blood and is one of the serine protease inhibitors (serpins). The primary function of C1INH is to regulate the activation of the complement and contact system pathways. Regulation of these systems is performed through the formation of complexes between the protease and the inhibitor, resulting in inactivation of both and consumption of the C1INH.
C1INH exerts its inhibitory effect by irreversibly binding several proteases (target proteases) of the contact and complement systems. The effect of Ruconest on the following target proteases was assessed in vitro: activated C1s, kallikrein, factor XIIa and factor XIa. Inhibition kinetics were found to be comparable with those observed for plasma-derived human C1INH.
Administration of Ruconest increases plasma levels of functional C1INH activity.
The complement component (protein) C4 is a substrate for activated C1. Patients with HAE have low levels of C4 in the circulation; Ruconest shows a dose-dependent restoration of complement homeostasis of C4 in HAE patients. A dose of 50 U/kg of Ruconest increases plasma C1INH activity levels to greater than 0.7 U/mL (the lower limit of normal) in HAE patients.
The pharmacokinetics of Ruconest was evaluated in a study of 12 asymptomatic HAE patients (dose ranged from 6.25 U/kg to 100 U/kg). Pharmacokinetics evaluation was performed by non-compartmental analysis, using functional C1INH levels. Following administration of Ruconest (50 U/kg) in asymptomatic HAE patients ( Table 5), the mean Cmax was 1.2 U/mL, and the elimination half-life was approximately 2.5 hours. The clearance of Ruconest was nonlinear (clearance decreased with increasing dose) over the dose range of 25-100 U/kg.
Studies have not been conducted to evaluate the PK of Ruconest in special patient populations, identified by race, age (pediatric or geriatric), or the presence of renal or hepatic impairment.
No animal studies have been conducted to evaluate the effects of Ruconest on carcinogenesis and mutagenesis. Fertility was not evaluated in animal studies.
Single- and repeat-dose studies of up to 14 days in rats, dogs, and cynomolgus monkeys with daily doses of Ruconest up to 80 times the human dose (50 U/kg) were conducted. In a 14-day monkey toxicology study of intravenous doses up to 2000 U/kg twice daily, increases in AST and ALP were observed at doses of 500 U/kg and higher. No histopathological correlates were observed in the liver and the increases in liver enzymes were reversible. Histologic findings included changes in the size of thymic cortex and medulla, and microvacuoles in the epithelial cells lining the renal tubules. The renal tubular vacuolation was dose dependent, but was not accompanied by other histological changes in the kidney. This finding was only partially reversible at the highest dose level of 2000 U/kg twice daily. It was concluded that the NOAEL of Ruconest was 1000 U/kg twice daily in this species. There were no adverse findings in a safety pharmacology study in dogs and a local tolerance study in rabbits. It is concluded that preclinical toxicology data for daily doses up to 40 times the proposed human dose of Ruconest (50 U/kg) do not indicate a safety concern for the use of Ruconest in humans.
Embryo-fetal studies have been conducted in rabbits and rats at a dose of Ruconest 12.5 times the human dose of 50 U/kg. In rats, no malformed fetuses were observed. In rabbits, an increase in the incidence of fetal cardiac vessel defects was observed (1.12% [2 cases] in the treatment group compared to 0.03% in historical controls). These defects are considered to be a chance finding, but a Ruconest-related effect cannot be excluded.
The safety and efficacy of Ruconest for treatment of acute angioedema attacks in patients with HAE was established in Study 1, a double-blind, randomized, placebo-controlled trial (RCT) which included an open-label extension (OLE) phase; and supported by the results of 2 additional RCTs and 2 additional OLE studies.
The safety and efficacy of Ruconest in the treatment of acute attacks in patients with hereditary angioedema were demonstrated in a placebo-controlled, double-blind, randomized study (Study 1). Supportive evidence of effectiveness is provided by two double-blind, randomized, placebo-controlled studies (Studies 2 and 3). Evidence for the efficacy of repeat treatment of HAE attacks is provided from the open-label extensions (OLE) of each of the three randomized studies.
Study 1 was a randomized, double-blind, placebo-controlled trial that included an open-label extension (OLE) phase to assess the efficacy and safety of Ruconest 50 U/kg in the treatment of acute attacks in patients with HAE. Seventy-five (75) adults and adolescent patients were randomized (3:2) to receive Ruconest 50 U/kg (N = 44) or placebo (N = 31). Patients ranged in age from 17 to 69 years of age; 63% were female and 37% were male; 96% were Caucasian.
The primary efficacy endpoint was the time to beginning of relief of symptoms, assessed using patient-reported responses to two questions from a Treatment Effect Questionnaire (TEQ). The TEQ required patients to assess the severity of their attack symptoms at each affected anatomic location, using a seven-point scale (“much worse” to “much better” [TEQ Question 1]), and whether their symptoms had begun to decrease notably since receiving the study medication (“yes” or “no” [TEQ Question 2]). To achieve the primary endpoint, a patient had to have a positive response to both questions along with persistence of improvement at the next assessment time (i.e., the same or better response).
Rescue treatment with Ruconest was available for patients who did not experience the beginning of relief at 4 hours after study drug administration, or earlier to patients who experienced life-threatening oropharyngeal-laryngeal angioedema symptoms. If a patient received a medication which could have impacted the efficacy evaluation or open-label Ruconest as rescue medication, prior to achieving beginning of relief of symptoms, the time to beginning of relief of symptoms was censored at the last assessed time prior to medication use.
In the RCT phase, the median time to beginning of relief of symptoms was statistically significantly shorter in patients treated with Ruconest 50 U/kg compared with patients treated with placebo as assessed by the TEQ; ( Table 6, Figure 1).
Values that are not estimable are displayed as ‘- ’.
Among several planned subgroup analyses, descriptive statistics showed that in US patients a median time to beginning of relief of symptoms with persistence at the primary attack location (based on TEQ) was 98 minutes [95% CI:(45, 240); n=22] for those receiving Ruconest and 90 minutes [95% CI: (50, -); n=16] for those receiving placebo. The hazard ratio for time to the beginning of relief of symptoms in this subpopulation was 1.20 [95% CI: 0.48 to 3.01] for patient receiving Ruconest as compared with patient receiving placebo. Non-US patients receiving Ruconest had a median time to beginning of relief of 90 minutes [95% CI: (63, 120); n=22] and non-US patients receiving placebo had a median time to beginning of relief of 334 minutes [95% CI: (150, -); n=15]. The hazard ratio for the non-US subgroup was 4.82 [95% CI: 1.58 to 14.72] for patients receiving Ruconest compared to placebo.
Examination of gender subgroups suggested a larger treatment effect in men than women. For women receiving Ruconest, the median time to beginning of relief was 113 minutes [95% CI: (63, 151); n=28], and for women receiving placebo, the median time to beginning of relief was 105 minutes [95% CI: (60, 334); n=19]. The hazard ratio for women receiving Ruconest versus placebo was 1.22 [95% CI: 0.60 to 2.48]. For men receiving Ruconest, the median time to beginning of relief was 75 minutes [95% CI: (45, 210); n=16], and for men receiving placebo, the median time to beginning of relief was 480 minutes [95% CI: (150, -) n=12]. The hazard ratio for men receiving Ruconest versus placebo was 3.94 [95% CI: 1.23 to 12.68].
No plausible biological explanations for the regional or gender subgroup effects were found. One possible explanation is a larger-than-expected placebo response among US women. None of the subgroup confidence intervals were adjusted for multiplicity.
Because almost all of the patients were Caucasian and were between 18 and 65 years of age, race and age subgroup analyses were not considered meaningful.
Among patients who achieved relief within 4 hours, there were 4 (27%) patients in the placebo group who had a relapse of their symptoms within 24 hours as compared with 1 (3%) in the Ruconest group. The proportion of patients who received Ruconest as rescue medication was greater in patients randomized to placebo (13 of 31 patients; 42%) than in patients randomized to Ruconest (5 of 44 patients; 11%).
The efficacy of Ruconest 50 U/kg for different anatomical locations of HAE attacks is summarized in Table 7.
In the OLE phase of Study 1, patients were treated with open-label Ruconest 50 U/kg for repeated attacks of HAE. Forty-four patients who completed the RCT phase were enrolled into the OLE phase where they were treated for a total of 170 attacks. In this phase, the median time to beginning of relief of symptoms was 75 minutes (95% CI: 64, 90), consistent with the results of the RCT phase of the study ( Table 6). Results were also comparable across attacks, suggesting that the efficacy of Ruconest 50 U/kg was maintained over repeated attacks of HAE. In the OLE phase of Study 1, 5/170 (3%) attacks received a second dose of Ruconest 50 U/kg.
In Study 2 (North American RCT), patients were randomized to receive a single administration of either Ruconest 50 U/kg (N=12), Ruconest 100 U/kg (N=13) or placebo (N=13). Patients ranged in age from 17 to 66 years of age; 74% were female and 26% were male; and 92% were Caucasian.
In Study 3 (European RCT), patients were randomized to receive a single administration of either Ruconest 100 U/kg (N=16) or placebo (N=16). Patients ranged in age from 17 to 71 years of age: 53% were female and 47% were male; and 100% were Caucasian.
Patients scored their symptoms using a visual analog scale (VAS) ranging from 0-100 mm. A VAS decrease of > 20 mm compared with baseline with persistence of the improvement at two consecutive time points was considered the onset of relief in Studies 2 and 3.
In both Study 2 and 3, the efficacy of Ruconest in the treatment of acute angioedema attacks was demonstrated by significantly shorter times to beginning of relief of symptoms based on the VAS (Figure 2).
In open-label extension studies of Study 2 and 3, 119 patients were treated with Ruconest for a total of 362 acute angioedema attacks. As observed in Study 1, the efficacy of Ruconest was maintained for repeat attacks.
Sulikowski T, Patston PA. The inhibition of TNK-t-PA by C1-inhibitor. Blood Coagul Fibrinolysis. 2001 Jan;12(1):75-7.
Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation. 1997 Aug 5;96(3):761-8.
Huisman LG, van Griensven JM, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost. 1995 Mar;73(3):466-71.
Gurewich V, Pannell R. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis. Thromb Haemost. 2009 Aug;102(2):279-86.
Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000 Mar;52(1):91-112.
German Medical Profession’s Drugs Committee [Arzneimittelkommission der deutschen Arzteschaft]. Severe thrombus formation of Berinert ® HS [Schwerwiegende Thrombenbildung nach Berinert ® HS]. Deutsches Ärzteblatt. 2000 April 2000; 97(Heft 15): A-1016.
Horstick, G, Berg O, Heimann A, Gotze O, Loos M, Hafner G, et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation. 2001 Dec 18;104(25):3125-31.
Ruconest is supplied in single-use 25 mL glass vials with a stopper (siliconized chlorobutyl rubber) and a flip-off seal (aluminum and colored plastic).
Each carton contains one single-use vial.
Each vial contains 2100 U rhC1INH lyophilized powder for reconstitution for injection.
Shelf life: 48 months when stored at 36ºF - 77ºF (2ºC - 25ºC).
Each vial of Ruconest should be reconstituted with 14 mL Water for Injection (not supplied). The reconstituted solution contains 150 U/mL rhC1INH and is clear and colorless.
Each vial of Ruconest is for single use only. Ruconest contains no preservative. Any product that has been reconstituted should be used immediately, or within 8 hours stored at 36ºF - 46ºF (2ºC - 8ºC). Discard partially used vials after treatment.
Advise the patient to read the FDA-Approved patient labeling (Product Information and Instructions for Use).
Patients being treated with Ruconest should receive the following information and instructions. This information is intended to aid the patient in the safe and effective use of Ruconest.
Advise female patients to notify their physician if they are pregnant or intend to become pregnant during the treatment of acute attacks of HAE with Ruconest.
Advise patients to notify their physician if they are breastfeeding or plan to breastfeed.
Inform patients of the risks and benefits of Ruconest before prescribing or administering it to the patient.
Signs and symptoms of allergic hypersensitivity reactions, such as hives, urticaria, tightness of the chest, wheezing, hypotension and/or anaphylaxis experienced during or after injection of Ruconest ( see WARNINGS AND PRECAUTIONS/Hypersensitivity [ 5] ).
Ruconest ® is a registered trademark of Pharming Intellectual Property B.V.
Product protected by U.S patent Nos. 7,067,713 and RE43691.
Please see www.Ruconest.com for patent information.
This leaflet summarizes important information about Ruconest. Please read it carefully each time before using Ruconest. There may be new information provided. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about Ruconest. If you have any questions after reading this, ask your healthcare provider.
Ruconest is an injectable medicine that is used to treat acute angioedema attacks in adult and adolescent patients with Hereditary Angioedema (HAE). HAE is caused by a shortage of a protein called C1 esterase inhibitor, that is present in your blood and helps control inflammation (swelling) and parts of the immune system. A shortage of C1 esterase inhibitor can lead to repeated attacks of swelling, pain in the abdomen, difficulty breathing and other symptoms. Ruconest contains C1 esterase inhibitor.
Who should not use Ruconest?
You should not use Ruconest if you have a known or suspected allergy (hypersensitivity) to rabbits or rabbit-derived products.
You should not use Ruconest if you have experienced life-threatening immediate hypersensitivity reactions, including anaphylaxis, to Ruconest or to any other C1 esterase inhibitor product.
Ruconest is not indicated for use in children under the age of 13 years.
What should I tell my healthcare provider before using Ruconest?
have an allergy to rabbits since this can put you at high risk of a serious allergic reaction with Ruconest. These allergy symptoms could include runny nose, itchy nose, sneezing, coughing, wheezing, difficulty breathing or watery eyes when you are near rabbits.
are pregnant or planning to become pregnant. It is not known if Ruconest can harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if Ruconest passes to your milk and if it can harm your baby.
Tell your healthcare provider and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies.
Ruconest will be slowly injected into your vein (intravenous injection). Before injection, the Ruconest powder must be dissolved using sterile Water for Injection. The dose will be determined based on your weight.
Most of the time a single dose of Ruconest is enough to treat an attack, but a second dose may be needed.
What are the possible side effects of Ruconest?
Like all medicines, Ruconest can cause side effects, although not everybody gets them.
In clinical studies, the most severe side effect reported in a person who received Ruconest was a severe allergic reaction in a subject who was allergic to rabbits.
If any of the side effects get serious, or if you notice any side effects not listed in the leaflet, please inform your healthcare provider or pharmacist. You can also report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or contact Pharming Healthcare Inc. at 1-800-930-5221.
You can ask your healthcare provider for information about Ruconest that is written for healthcare providers.
Do not use Ruconest for a condition for which it is not prescribed.
If you would like more information, talk to your healthcare provider. You can ask your healthcare provider or pharmacist for information about Ruconest that was written for healthcare professionals.
For more information go to www.Ruconest.com or call 1-800-930-5221.
Use aseptic (sterile) technique when preparing and administering Ruconest.
Step 1: Assemble supplies from medication box on a clean flat surface.
Sterile Water for Injection (diluent), 14mL per vial of Ruconest to be reconstituted.
Needle-free, vented or non-vented vial adapters (or large bore needle). Use a new vial adapter for each vial of Ruconest and diluent.
Discuss this section with your healthcare provider to ensure that the correct dose of Ruconest is administered.
The dose of Ruconest and volume (mL) of reconstituted solution to be administered is based on body weight show in the chart below. No more than 2 vials may be combined for a single dose.
The procedures below are provided as general guidelines for the reconstitution of Ruconest.
Step 1: Ensure that the Ruconest vials and the diluent vial are at room temperature (range of 68°F - 77°F or 20°C - 25°C).
Wipe the vial stoppers with the antiseptic wipes provided and allow to dry for 30 seconds.
Do not blow on the stoppers after wiping.
Do not touch the stopper with your hands, or allow it to touch any surface.
Step 3: Peel back the covers from the clear plastic vial adapter packages.
Leave the adapters in their packages.
Step 4: While holding the adapter in its package, place the first adapter over the diluent vial and press down until the device snaps into place.
Leave the package on the adapter until you are ready to attach the syringe.
Step 5: Now, place a 2nd adapter over a Ruconest vial and press down until it snaps into place.
Repeat if your dose requires a 2nd Ruconest vial.
Step 6: Lift the package away from the diluent adapter.
Step 7: Remove syringe from package and withdraw sterile water for injection from the diluent vial.
With vial on a flat surface, attach syringe to adapter on diluent vial by rotating syringe clockwise.
Turn diluent vial upside down and slowly withdraw either 14 mL (if using 1 Ruconest vial) or 28 mL (if using 2 Ruconest vials) of diluent into syringe by gently pulling back on the plunger.
There will still be some diluent left in the vial.
Place the diluent vial back on a flat surface and detach syringe by gently pulling the syringe and rotating counterclockwise.
Step 8: Transfer the diluent to the Ruconest vial.
Remove the package from the adapter connected to one of the Ruconest vials.
Attach the syringe holding the diluent to the adapter on the Ruconest vial by inserting the tip into the adapter opening while firmly pushing and rotating the syringe clockwise.
Slowly press 14 mL of diluent into the Ruconest vial.
Add the diluent slowly to avoid forceful impact on the powder.
Note: Leave the syringe attached to the vial after adding the diluent.
Step 9: Swirl the vial to mix. Do this slowly to avoid foaming.
Repeat Steps 8 and 9 if you are using a second Ruconest vial. Remove syringe from the first Ruconest vial prior to attaching to the second vial.
Step 10: Inspect Ruconest vial(s) visually.
After reconstitution and prior to administration, inspect the Ruconest vials visually for particulate matter and discoloration.
The reconstituted solution should be colorless, clear, and free from visible particles.
Do not use the vial if it looks cloudy, contains particles, or has changed color.
Step 11: With the syringe still connected to the Ruconest vial, turn the vial upside down.
Slowly withdraw your dose of Ruconest by gently pulling back on the plunger.
Once you have withdrawn your dose, turn the vial right side up and place on a flat surface. Disconnect the syringe by gently pulling and rotating counterclockwise.
Step 12: Repeat Step 11 and withdraw additional reconstituted Ruconest from the second Ruconest vial (if needed).
Withdraw only as much as is needed based on your body weight.
Disconnect the syringe, for use as described in the next section.
Your healthcare provider will teach you how to safely administer Ruconest. It is important that you inject Ruconest directly into a visible vein. Do not inject into surrounding tissues or an artery. Once you learn how to self-administer, follow the instructions provided below. The reconstituted solution should be used within 8 hours and should be cooled but not be frozen.
Thoroughly clean a table or other flat surface using one or more of the antiseptic wipes.
Step 3: Prime the infusion set.
To prime (fill) the infusion tubing, connect the syringe filled with Ruconest to the infusion set tubing and gently push on the syringe plunger to fill the tubing with Ruconest.
Step 4: Prepare the approved IV injection site.
Apply a tourniquet above the site of the infusion.
Prepare the injection site by wiping the skin well with an antiseptic wipe, beginning at the center and working outward in a circular motion.
Allow the site to dry.
Follow the instructions provided by your healthcare provider.
Take off the needle sheath.
Hold both wings of the butterfly between the thumb and the index finger with the obliquely cut (slanted) opening of the butterfly needle pointing upward.
Insert the butterfly needle of the infusion set into your vein (insert as flat to skin surface as possible).
Use sterile gauze and tape or transparent dressing to hold the needle in place.
Gently pull back on the syringe plunger and check to see if blood is in the tubing.
If there is blood present, then the needle is in a vein.
If there is no blood, remove the needle and repeat this step using a new needle, new administration tubing, and a different injection site.
Note: Inject Ruconest slowly over approximately 5 minutes.
Step 6: Cover the injection site and clean up.
Withdraw the butterfly needle along the line that it was inserted.
Cover the injection site with a bandage, holding pressure on the site for a few minutes.
Dispose of all unused solution, empty vials, and used needles and syringe in an appropriate container used for medical waste.
The procedures below are provided as general guidelines for after the infusion of Ruconest.
Record each injection into treatment journal.
Record the lot number from the Ruconest vial label.
Enter the date and time of your injection.
This Patient Package Insert has been approved by the US Food and Drug Administration.
Product protected by U.S. patent Nos. 7,067,713 and RE43691.
See prescribing information for directions for use.


text:
The Richard and Pat Johnson Palm Beach County History Museum is a countywide museum that enriches the lives of children and adults alike by making local history accessible, interesting, and meaningful.This museum is housed in the spectacular 1902 mansion built by Henry Flagler as a gift for his bride, Mary Lily Kenan.
While these Palm Beach County museums vary in price, they are all very affordable — and all will further your knowledge about the culture of Palm Beach County.
Find individual business listings for businesses located within the city of Palm Beach in Florida.The Art of Tea Museum Exhibit on Jan 28, 2019 in West Palm Beach, FL at Wiener Museum of Decorative Arts.The Art of Tea Museum Exhibit on Jan 24, 2019 in West Palm Beach, FL at Wiener Museum of Decorative Arts. Here are some top art museums in Palm Beach that are well worth a visit. 1) Boca Museum of Art in Mizner Park. 2) Norton Museum of Art, located at South Olive Avenue, West Palm Beach. 3) Cornell Museum of Art and American Culture, Delray Beach.
The Flagler Museum in Palm Beach, FL, is dedicated to the artistry of the Gilded Age America.
Visit the Norton Museum on Facebook Visit the Norton Museum on Twitter Visit the Norton Museum on Instagram 1450 S.
Plan a Visit to Any of the Best Museums in West Palm Beach, Check Events, Exhibits, Admission, Hours and more.In addition to offering climbing tours of the landmark 1860 lighthouse, we are the proud site of the Jupiter Inlet Lighthouse Outstanding Natural Area, National Conservation Lands.
Across the Intracoastal Waterway in West Palm Beach is the Norton Museum of Art, created in 1941 by steel industrialist Ralph Hubbard Norton and his wife, Elizabeth Calhoun Norton.It will offer its Gilded Age-style tea lunches daily, except Mondays, through April 21. Norton retired from the steel industry, he created the Norton Museum of Art to hold his impressive art collection. Since its.
The primary focus of the Palm Beach Museum of Natural History is to research, interpret, and explain the natural history and archaeology of southern Florida, to include its place within the context of the wider Caribbean region.Luckily, that includes a wide variety of museums and other cultural attractions.
The maritime museum is actually a collection of maritime buildings, of which one of its most popular is the Historic Former Coast Guard Station, located on Peanut Island.
Plan your road trip to Palm Beach Maritime Museum in FL with Roadtrippers. Our replicas are produced especially for your order and may take 4 to 6 weeks for smaller items and up to 4 months for larger skeletons.
Check out our guide on South Florida Science Museum in Palm Beach - West Palm Beach so you can immerse yourself in what Palm Beach - West Palm Beach has to offer before you go. Hotel rooms are offered at the lowest price on Agoda.com with many of them in the vicinity of Museums and Art Galleries.
For more than 70 years, The Society of the Four Arts has been the cultural destination of Palm Beach, providing concerts, lectures, films, art exhibitions and more to the community.
Set in Palm Beach, Hemingway Suite at Palm Beach Hotel Island provides air-conditioned accommodations with access to a garden.
Get offline map and directions using our GPSmyCity self-guided walking tours app for your mobile device.
Palm Beach Maritime Museum The education center and museum in Currie Park has exhibits dedicated to preserving the early maritime history of the Palm Beach area and shows the influence that the sea, and particularly the Gulf Stream, has had on the settlement and growth of this area. University of Florida Vertebrate Fossil Locality PB002. Location. The site is located about 7 miles (12 km) west of downtown West Palm Beach in the Golden Lakes community, Palm Beach County, Florida.Palm Beach County Convention Center is a 350,000-square-foot meeting space, exhibit hall and ballroom just three miles from Palm Beach International Airport in West Palm Beach and only 20 minutes from the resort.When you live in the Palm Beach area, you can feel confident that there is always something fun and exciting to do.
The museums Coney Island theme features much of the memorabilia that is reminiscent of the iconic amusement park.